Effect of SGLT2i in NAFLD
| Author, year . | Agent . | n . | Duration (weeks) . | Comparator . | Main study results . | ||
|---|---|---|---|---|---|---|---|
| Body weight* . | ALT . | Liver fat* . | |||||
| Prospective open-label studies | |||||||
| Ito et al., 2017 (42) | Ipragliflozin | 66 | 24 | Pioglitazone | ↓ 3.7% | ↓ | ↓¶ |
| Ohta et al., 2017 (43) | Ipragliflozin | 20 | 24 | Standard care | ↓ 2.5% | ↓ | ↓ 39% |
| Shibuya et al., 2018 (44) | Luseogliflozin | 32 | 24 | Standard care | ↓ 3.2% | Unchanged | ↓¶ |
| Kuchay et al., 2018 (45) | Empagliflozin | 50 | 20 | Standard care | ↓ 1.1% | ↓ | ↓ 26% |
| Shimizu et al., 2019 (46) | Dapagliflozin | 57 | 24 | Standard care | ↓ 3.1% | ↓ | ↓† |
| Inoue et al., 2019 (47) | Canagliflozin | 20 | 52 | Standard care | ↓ 3.4% | ↓ | ↓ 31% |
| Randomized controlled trials | |||||||
| Bolinder et al., 2012 (48) | Dapagliflozin | 67 | 24 | Placebo | ↓ 2.2% | — | Unchanged |
| Eriksson et al., 2018 (49) | Dapagliflozin | 84 | 12 | Placebo | ↓ 2.2% | ↓ | ↓ 10%§ |
| Cusi et al., 2019 (50) | Canagliflozin | 56 | 24 | Placebo | ↓ 3.4% | Unchanged | ↓ 18%§ |
| Latva-Rasku et al., 2019 (51) | Dapagliflozin | 32 | 8 | Placebo | ↓ 2.1% | Unchanged | ↓ 13% |
| Kahl et al., 2019 (52) | Empagliflozin | 84 | 24 | Placebo | ↓ 2.4% | Unchanged | ↓ 22% |
| Author, year . | Agent . | n . | Duration (weeks) . | Comparator . | Main study results . | ||
|---|---|---|---|---|---|---|---|
| Body weight* . | ALT . | Liver fat* . | |||||
| Prospective open-label studies | |||||||
| Ito et al., 2017 (42) | Ipragliflozin | 66 | 24 | Pioglitazone | ↓ 3.7% | ↓ | ↓¶ |
| Ohta et al., 2017 (43) | Ipragliflozin | 20 | 24 | Standard care | ↓ 2.5% | ↓ | ↓ 39% |
| Shibuya et al., 2018 (44) | Luseogliflozin | 32 | 24 | Standard care | ↓ 3.2% | Unchanged | ↓¶ |
| Kuchay et al., 2018 (45) | Empagliflozin | 50 | 20 | Standard care | ↓ 1.1% | ↓ | ↓ 26% |
| Shimizu et al., 2019 (46) | Dapagliflozin | 57 | 24 | Standard care | ↓ 3.1% | ↓ | ↓† |
| Inoue et al., 2019 (47) | Canagliflozin | 20 | 52 | Standard care | ↓ 3.4% | ↓ | ↓ 31% |
| Randomized controlled trials | |||||||
| Bolinder et al., 2012 (48) | Dapagliflozin | 67 | 24 | Placebo | ↓ 2.2% | — | Unchanged |
| Eriksson et al., 2018 (49) | Dapagliflozin | 84 | 12 | Placebo | ↓ 2.2% | ↓ | ↓ 10%§ |
| Cusi et al., 2019 (50) | Canagliflozin | 56 | 24 | Placebo | ↓ 3.4% | Unchanged | ↓ 18%§ |
| Latva-Rasku et al., 2019 (51) | Dapagliflozin | 32 | 8 | Placebo | ↓ 2.1% | Unchanged | ↓ 13% |
| Kahl et al., 2019 (52) | Empagliflozin | 84 | 24 | Placebo | ↓ 2.4% | Unchanged | ↓ 22% |
Arrows indicate statistically significant changes vs. comparator.
Comparison-corrected (open-label) or placebo-corrected relative treatment difference in weight and liver fat measured with MRI-based imaging techniques.
Liver fat measured as liver-to-spleen attenuation ratio on computed tomography. In Ito et al. (42) the decrease in liver fat was similar to pioglitazone (comparator).
Significant improvement in liver fat by controlled attenuation parameter (CAP; Fibroscan).
Not significant compared with placebo.